About Us

IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.

IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.

Mission

Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.

Discription of Business

  • IPG will conduct non-clinical R&D steps efficiently to create clinical candidates for new drugs, and create intellectual property (e.g., patents) by utilizing not only ADDP’s promising drug seeds, inherited from Takeda Pharmaceutical Company Limited, but also innovative drug discovery concepts of global academic institutions.
  • IPG will license out the new drug candidates to pharmaceutical companies around the world, and monetize them (up-front payment and royalties).
  • IPG membership has been established as a key driver of the above IPG’s business.

Membership

  1. Registered Membership Program
  2. No membership fee
  3. Members can review IPG projects under development by IPG and receive progress reports.
  4. Members can exchange information with IPG on target diseases and drug targets of interest to them and express their willingness to adopt IPG’s projects.

Company Profile

Name of the CompanyIPGaia, Inc.
Location2-5-1 Atago, Minato-ku, Tokyo 105-6236
InvestorHealthcare New Platform Fund(100%)
General Partner; Whiz Partners Inc.
Capital and Capital Reserves10 million JPY
EstablishedOctober 26th, 2021
Business Scope
  1. R&D and sales of pharmaceuticals
  2. Business in increasing the value of intellectual property and selling usage rights
  3. All other businesses incidental and related to the above
ManagementPresident & CEO
Chairman
Yasunori Yamaguchi
Satoru Iino

Press Release

Press Release

IPGaia, Inc. and UC San Diego Announce Master Collaborative Research and Development Agreement

IPGaia, Inc., (“IPG”) and University of California San Diego (“UC San Diego”), based in La Jolla, California, USA, have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated July 1st, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from UC San Diego into IPG’s drug discovery platform.   Following UC San Diego’s strong history of partnering with industry to advance drug discovery, the program enables UC San Diego to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. For patients, personalized medicine holds great …

Notice of Company Name Change and New President & CEO Assume Office

IP Generator, Inc. (Headquarter: Minato Tokyo, President & CEO: Satoru Iino) will change its name to the following as of July 1, 2022, to further strengthen its business foundation with a new management team. 1. Company Name Change New company name:IPGaia, Inc. (Hereinafter, “IPG”) Background :”Gaia” is a primordial god that has existed since the beginning of the world in ancient Greek mythology. We have decided to name our company “IP Gaia” with the passion to contribute to society by improving medical access and reducing medical costs as a drug discovery platformer that efficiently generates high-quality clinical development candidates from drug seeds, which is a new beginning in Japan. 2. …

IP Generator, Inc. and RIKEN Announce Drug Discovery Alliance Agreement

IP Generator, Inc., (“IPG”) and National Research and Development Institute, RIKEN (“RIKEN”), based in Saitama, Japan, have entered into a Drug Discovery Alliance Agreement (“this agreement”) dated June 3, 2022. This agreement, executed with the support of RIKEN Innovation Co., Ltd. (RIKEN Innovation), establishes a formal framework for the incorporation of promising drug target leads from RIKEN into IPG’s drug discovery platform. The program enables RIKEN to propose drug seeds to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG aims for the efficient creation of innovative medicines and hopes to contribute to solving global social issues …